Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report

BACKGROUND: Currently, immune checkpoint (ICP) inhibitors are essential drugs for the treatment of non-small cell lung cancer (NSCLC). However, in patients previously treated with ICP inhibitors, the efficacy and safety of re-challenging the same or another ICP inhibitor remain unclear. CASE PRESENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Hakozaki, Taiki, Okuma, Yusuke, Kashima, Jumpei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859734/
https://www.ncbi.nlm.nih.gov/pubmed/29554874
http://dx.doi.org/10.1186/s12885-018-4212-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859734/
https://www.ncbi.nlm.nih.gov/pubmed/29554874
http://dx.doi.org/10.1186/s12885-018-4212-1

Ejemplares similares